Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening

Similar documents
Playing Detective: going in search of the source of infection. Su Brailsford Consultant in Epidemiology and Health Protection

Hepatitis E and the English blood supply

Lookback studies to assess viral risks The French experience

Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:

Annual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI)

Chapter 17: Transfusion-Transmitted Infections (TTI)

Transfusion-transmitted Cytomegalovirus

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P

CTYOMEGALOVIRUS (CMV) - BACKGROUND

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen

Impact of multi-dye multiplex technology on testing algorithm

Surveillance Report 2014

Public Health, Infections and Transplantation

Infectious Disease Considerations in Organ Donation. Nikole A Neidlinger MD FACS Chief Medical Officer

New recommendations for immunocompromised patients

Anticipating (re)emerging infections to ensure blood safety

Guide to the preparation, use and quality assurance of blood components

The testing of Donated Blood and Components at NHSBT

July 14, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Guidance for Industry

Change in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion

Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil,

June 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

Surveillance Report 2016

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

Surveillance Report 2015

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

Congenital CMV infection. Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. APPENDICES a TO GUIDELINE ON EPIDEMIOLOGICAL DATA ON BLOOD TRANSMISSIBLE INFECTIONS

BACTERIAL INTERVENTIONS TO INCREASE BLOOD SAFETY

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

R Offergeld, D Faensen, S Ritter, O Hamouda Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.

Source Plasma Safety

Guidance for Industry

Dengue Fever & Dengue Hemorrhagic Fever Annual Reports to WHO

AdvaMedDx Value Assessment Framework in Practice

RISK OF DISEASE TRANSMISSION FROM ORGAN DONORS PATIENT INFORMATION GUIDE

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.

Copyright, 1995, by the Massachusetts Medical Society

transfusion-transmissible HCV and HIV in Italy Haemovigilance and the residual risk of

Hepatitis C Best Practice Guidelines For Local Health Departments

Non-reproductive tissues and cells Recommending authority/ association

Test Name Results Units Bio. Ref. Interval

Guidance for Industry

The Alphabet Soup of Viral Hepatitis Testing

NAT Screening of Blood Donations in NBC, TRCS

The Immune Response to Parvovirus B19 Exposure in Previously Seronegative and Seropositive Individuals

HEV Update Blood Components. Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden)

Patient Name: MRN: DOB: Treatment Location:

Adverse Reactions Associated with Methylene Blue Inactivated Fresh Frozen Plasma (MB FFP)

Pandemic Flu, MERS-CoV, Ebola! What's next? What are we doing about emerging infections?

What You Need to Know About Blood Transfusion. Elianna Saidenberg May 2014

Hot Topics in Tissue Safety

Laboratory reports of hepatitis A and C infection in England and Wales: January to March

HIV and AIDS. Lesson. By Carone Fitness. HIV and AIDS

Consent and donor choice in lung and heart-lung transplantation

DENGUE AND BLOOD SAFETY. Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo

Commonly Asked Questions About Chronic Hepatitis C

your liver Care for Think about hepatitis

CHART ELEVEN (11) KENYAN FIGURES (KENYA DEMOGRAPHIC HEALTH SURVEY REVISED 2004)

Malaria screening of donors and donations - issues and outcomes

Overview of Blood Transfusion System of Iran:

What is HIV? An educational booklet supported by:

Instruction to implement measures for risk minimisation in using HIV-1 NAT test systems

[Submitted Electronically]

An Audit of Emergency Group O blood use in Royal Devon and Exeter Hospital

BLOOD DONATION OR BLOOD DONOR DEFERRAL BASED ON DATA ON NONCONFORMITIES DETECTED IN POST-SELECTION PERIOD (DURING AND AFTER BLOOD COLLECTION)

The how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV?

HLA Selected Platelets

Plasma for fractionation: South African Plasma Requirements

Khalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia

L 256/32 Official Journal of the European Union

Achieving Consensus on Increased Risk Donors to Improve Access to Organ Transplantation Executive Summary

ARBOVIRAL RISKS TO BLOOD SAFETY IN AUSTRALIA. Clive Seed Australian Red Cross Blood Service ISBT TTD-WP meeting 26 June, 2015

Hepa%%s E Virus Is it a Concern?

Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E.

Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey

UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication

Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors

Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience

Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid Amplification Testing

Source of effectiveness data Effectiveness data were derived from a single study combined with a review of previously completed studies.

INITIAL EVALUATION AND MANAGEMENT FOLLOWING EXPOSURE TO BLOOD OR BODY FLUIDS

Diagnosis of Acute HCV Infection

Sensitivity of the Procleix HIV-1/HCV Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA in a High-Risk Population

Interventions for Babesia (and Plasmodium)

U.S. changes in Kidney Allocation

ANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES

20. HIV and AIDS. Objectives. How is HIV transmitted?

Professor Adrian Mindel

Transplants. Mickey B. C. Koh

Overview of Organ Donation and Transplantation

2017 CST-Astellas Canadian Transplant Fellows Symposium. Optimizing use of organs from Increased Risk Donors

PUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 9291

HIV Lecture. Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital

Transcription:

Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening Bhavita Vishram

Timeline of introduction of microbiological tests for blood donations, UK

Window period Developed from Schriber et al NEJM 1996 by Soldan et al Vox Sang 2003; Eurosurveillance 2005

The current risk of not detecting an HIV infectious donation is much less than 1 per million donations.

Lookback investigations I HIV positive repeat blood donor most recent previous negative donation (MRPD) possibility that previous donation was infectious but not detected donated in window period or false negative. lookback testing archives, tracing fate of components made from MRPD and arranging notification of living recipients. introduction of NAT screening and Ab/Ag assays reduced chance of false negative.

Lookback investigations II positive repeat donor donor contacted and offered a post test discussion with a NHSBT clinician. stored archive sample (kept for 3 years) tested in an individual sample HIV PCR test. irrespective of the result, a lookback is often carried out to determine fate of blood components. lookback may not be carried out where other information points to the infection having being acquired a later date. clear history of seroconversion illness credible risk for infection in the donor with postdates the MRPD. the results of all lookbacks are collated by the NHSBT/PHE Epidemiology unit.

Case 1 male donor - late 20 s donation in November 2016- previous donation March 2016 avidity seroconversion may have occurred within 4 months of donation archive sample HIV PCR negative. history of new female partner after MRPD seroconversion illness in June with high fever, diarrhoea, vomiting and night sweats. NO LOOKBACK CONDUCTED

Case 2 male - Mid 40 s donation in January 2015 - previous donation September 2014. one off sexual contact with another male no clear history archive sample was HIV PCR negative LOOKBACK CONDUCTED Red cells transfused - recipient identified, tested HIV negative Platelets transfused recipient identified deceased before lookback conducted

Where archive samples test negative on singleton PCR do we need to continue HIV lookback investigations?

Data from 1995 to 2008

Data from 1995 to 2008 Byrne et al. 2011 Transfusion

Data from 2009 to 2016

Results archive samples 65 HIV positive repeat donors 60 seroconverted within 3 years 53 archive samples tested negative 7 3 archive samples unavailable 4 archives not tested due to donor history and avidity showing recent infection

Results lookback investigations 33 lookback investigations 32 recipients 10 deceased 18 tested HIV negative 4 outcome unknown NO HIV TRANSMISSIONS WERE IDENTIFIED

since the introduction of pooled HIV NAT screening in 2003: 4 HIV window period donations (NAT pick ups) detected by screening; negative on HIV serology but reactive on pooled HIV NAT screening. no cases of HIV transmission detected by lookback investigations since routine NAT screening was introduced within NHSBT.

Where archive samples test negative on singleton PCR do we need to continue HIV lookback investigations?

NHSBT governance committee recently approved no lookback is needed where archive samples test HIV PCR negative.

Conclusion HIV screening has improved in sensitivity over the last 20 years. 4 window period donations have been detected through screening of 21 million donations from 2003-2016. number of window period donations not detected through the use of pooled HIV NAT screening will be vanishingly small and lookback has failed to detect any. discontinue lookback investigations where archive samples HIV PCR negative.

Acknowledgements Dr Patricia Hewitt Dr Su Brailsford Claire Reynolds Katy Davison All staff in hospitals who have helped in collecting information.